TABLE 1.
Characteristics of treated individuals from cohorts in five countries (United States, Egypt, UK, Georgia and Myanmar) and from clinical trials from two pharmaceutical companies
| US Veterans Affairs20, b | Egypt21, a | United Kingdom22, b | Georgia19, a | Myanmar23, d | Ukraine24, d | Médecins Sans Frontières** (multi‐country) c |
Clinical Trial Registry 125, e (multi‐country) |
Clinical Trial Registry 226, e (multi‐country) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
| Total | 174,889 | 337,042 | 24,592 | 52,856 | 763 | 868 | 2,904 | 5,033 | 624 | |||||||||
| Age (years) | ||||||||||||||||||
| Mean ± SD | 60 ± NA | 50 ± 11 | 51 ± 12 | NA | 38 ± 11 | 39 (35–45)* | 50 ± 12 | NA | 54 ± NA | |||||||||
| Sex | ||||||||||||||||||
| Male | 169,642 | 97% | 182,008 | 54% | 17,288 | 70% | 41,175 | 78% | 618 | 81% | 573 | 66% | 1183 | 41% | 2774 | 55% | 374 | 60% |
| Female | 5247 | 3% | 155,034 | 46% | 7304 | 30% | 11,681 | 22% | 145 | 19% | 295 | 34% | 1721 | 59% | 2259 | 45% | 250 | 40% |
| Per cent SVR at 12 weeks | >90% | 68%–99% | 95% | 98% | 78%–100% | 96% | 96% | 90%–100% | 99% | |||||||||
| HCV genotype | ||||||||||||||||||
| 1 | 139,911 | 80% | 12,134 | 4% | 13,353 | 54% | 23,309 | 62% | 69 | 9% | 643 | 74% | 941 | 32% | 2,388 | 47% | 328 | 53% |
| 2 | 20,987 | 12% | 1348 | <1% | 1057 | 4% | 10,518 | 11% | 8 | 1% | 20 | 2% | 116 | 4% | 1,054 | 21% | 104 | 17% |
| 3 | 12,242 | 7% | 674 | <1% | 8878 | 36% | 18,024 | 27% | 366 | 48% | 191 | 22% | 483 | 17% | 1,140 | 23% | 0 | 0% |
| 4–6/missing | 1749 | 1% | 322,886 | 96% | 1303 | 5% | 1004 | 0% | 320 | 42% | 14 | 2% | 1364 | 47% | 451 | 9% | 76 | 12% |
This table represents the general population of those treated in each location, but is not representative of the treated population that yielded the detectable viral loads in this study.
Abbreviations: HCV, hepatitis C virus; NA, not available; SD, standard deviation; SVR, sustained virologic response.
Registries from country‐wide national HCV ministries of health.
Large health care systems.
Non‐governmental organizations with programmatic data including across multiple countries This was the only sample for which we had data on individuals who attained SVR as well as those with detectable viral at 12 weeks, and present the characteristics of that cohort here.
Specific funded research projects.
clinical trials registries from two large pharmaceutical companies (Gilead and AbbVie).
Age data from Ukraine are reported as median and interquartile range.
Data are routinely collected from MSF program sites in Mozambique, Cambodia and Pakistan.